DDC and Parkinson disease: Levodopa is the most commonly used treatment for PD and is usually co-administered with an aromatic L-amino acid decarboxylase inhibitor to increase bioactivity, since levodopa is rapidly metabolized to dopamine by peripheral aromatic L-amino acid decarboxylase and catechol-O-methyltransferase (Rocha et al., 2017).